Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun, China.
Am J Hypertens. 2014 Jan;27(1):27-31. doi: 10.1093/ajh/hpt138. Epub 2013 Aug 19.
Amlodipine has been shown to improve vascular endothelial function in hypertensive patients, but whether S(-)-amlodipine has a similar effect remains controversial. This study compared the effects of amlodipine and S(-)-amlodipine on vascular endothelial function in hypertensive patients and investigated relevant mechanisms of action in cell culture.
Twenty-four patients with essential hypertension received amlodipine and S(-)-amlodipine for 6 weeks in a randomized, crossover study. Associated flow-mediated dilation (FMD), nitric oxide (NO), and endothelial nitric oxide synthase (eNOS) levels were determined. NO levels were measured after exposure of human umbilical vein endothelial cells (HUVECs) to amlodipine, S(-)-amlodipine, the eNOS inhibitor N w-nitro-L-arginine (L-NA), and the Protein Kinase C (PKC) inhibitor Ro 31-8220. Phosphorylation levels of Ser(1177) and Thr(495) in eNOS were determined after exposure to amlodipine, S(-)-amlodipine, and Ro 31-8220.
FMD, NO, and eNOS levels significantly improved after treatment with amlodipine and S(-)-amlodipine. The levels were all higher with amlodipine, although the between-treatment difference was not statistically significant. Amlodipine and S(-)-amlodipine significantly increased NO levels in cultured HUVECs, but increases in NO levels were more marked with amlodipine. Western blot assay showed that both amlodipine and Ro31-8220 induced Ser(1177) phosphorylation and weakened Thr(495) phosphorylation in eNOS. S(-)-amlodipine had no similar effects. Amlodipine, but not S(-)-amlodipine, decreased the PKC phosphorylation in a time-dependent manner.
Amlodipine and S(-)-amlodipine can both improve endothelial function in hypertensive patients. Amlodipine has greater potential for vascular endothelial protection than S(-)-amlodipine. It affects eNOS phosphorylation at Ser(1177) and Thr(495) by the PKC pathway, further enhancing eNOS activation.
氨氯地平已被证明可改善高血压患者的血管内皮功能,但 S(-)-氨氯地平是否具有类似作用仍存在争议。本研究比较了氨氯地平和 S(-)-氨氯地平对高血压患者血管内皮功能的影响,并在细胞培养中研究了相关作用机制。
24 例原发性高血压患者接受氨氯地平和 S(-)-氨氯地平的随机、交叉研究 6 周。测定相关的血流介导的扩张(FMD)、一氧化氮(NO)和内皮型一氧化氮合酶(eNOS)水平。将人脐静脉内皮细胞(HUVEC)暴露于氨氯地平、S(-)-氨氯地平、eNOS 抑制剂 Nω-硝基-L-精氨酸(L-NA)和蛋白激酶 C(PKC)抑制剂 Ro 31-8220 后,测定 NO 水平。暴露于氨氯地平、S(-)-氨氯平和 Ro 31-8220 后,测定 eNOS 中 Ser(1177)和 Thr(495)的磷酸化水平。
氨氯地平和 S(-)-氨氯地平治疗后 FMD、NO 和 eNOS 水平显著改善。虽然治疗之间的差异没有统计学意义,但氨氯地平的水平更高。氨氯地平和 S(-)-氨氯地平均显著增加培养的 HUVEC 中的 NO 水平,但氨氯地平的增加更为显著。Western blot 检测显示,氨氯地平和 Ro31-8220 均诱导 eNOS 中 Ser(1177)的磷酸化,并减弱 Thr(495)的磷酸化。S(-)-氨氯地平则没有类似作用。氨氯地平而非 S(-)-氨氯地平可呈时间依赖性降低 PKC 磷酸化。
氨氯地平和 S(-)-氨氯地平均可改善高血压患者的内皮功能。氨氯地平比 S(-)-氨氯地平具有更大的血管内皮保护作用。它通过 PKC 通路影响 eNOS 中 Ser(1177)和 Thr(495)的磷酸化,进一步增强 eNOS 的激活。